stockrow
Friday 6 November 2026
Export BIAF’s income statement to Excel — free account
bioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
bioAffinity Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 million, down 34.2% from fiscal 2024.
- Revenue
- +19.0%
- EPS
- +87.5%
- Free cash flow
- −23.7%
- Total debt
- +569.7%
Quarter to June 2026, against a year earlier
2.74
0.14
+5.38%
Follow BIAF
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.47 | 0.33 | 3.04 | 0.72 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.27) | (0.79) | (5.34) | (1.33) | |
P/B ratio |
0.35 | 0.28 | 4.70 | 1.13 | |
Price to Tangible BV |
0.47 | 0.39 | 11.08 | 2.53 | |
EV/Sales |
(0.64) | (0.61) | 2.60 | 0.40 | |
EV/EBITDA |
0.44 | 0.37 | 0.00 | 0.00 | |
EV/Operating CF |
0.51 | 0.40 | (1.35) | (0.21) | |
EV/FCF |
0.51 | 0.40 | (1.35) | (0.21) | |
Quick Ratio |
3.44 | 2.41 | 1.19 | 1.24 | |
Current Ratio |
3.65 | 2.60 | 1.36 | 1.44 | |
Net Debt/EBITDA |
3.44 | 1.92 | 0.71 | 0.57 | |
Debt/Assets |
1.58% | 6.20% | 7.74% | 7.28% | |
Debt/Equity |
0.02 | 0.09 | 0.17 | 0.15 | |
Asset Turnover |
0.75 | 0.71 | 0.84 | 0.95 | |
Operating CF/Net income |
0.49 | 0.82 | 0.89 | 0.95 | |
Capex/Depreciation |
0.03 | 0.00 | (0.05) | (1.46) | |
Interest Coverage |
(424.59) | (239.47) | (246.05) | (285.03) | |
Research and Development Expense of Revenue |
32.77% | 41.99% | 50.59% | 55.44% | |
Selling, General and Administrative Expense of Revenue |
152.78% | 190.68% | 239.85% | 189.24% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.27 | 0.27 | |
Share Based Compensation of Revenue |
4.65% | 4.15% | 1.06% | 51.97% | |
Graham Net Nets |
1.89 | 1.91 | 0.00 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(707.62%) | (1,300.30%) | (296.36%) | (848.27%) | |
Free Cash Flow Yield |
(269.48%) | (462.09%) | (63.46%) | (272.26%) | |
Revenue per Share |
20.34 | 13.87 | 4.51 | 4.33 | |
Operating CF per Share |
(34.88) | (22.30) | (10.76) | (9.18) | |
Capex per Share |
0.05 | 0.00 | (0.02) | (0.26) | |
Free Cash Flow per Share |
(34.83) | (22.30) | (10.78) | (9.44) | |
Cash per Share |
107.87 | 56.18 | 10.33 | 6.97 | |
Shareholders Equity per Share |
125.21 | 63.39 | 12.21 | 10.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
125.21 | 63.39 | 12.21 | 10.81 | |
Free Cash Flow |
(2.48) | (2.56) | (3.23) | (3.29) | |
Working Capital |
6.25 | 4.66 | 1.16 | 1.18 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | (0.09) | |
Net Current Asset Value |
5.97 | 3.88 | 0.06 | 0.01 | |
EV/EBIT |
0.42 | 0.35 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.89 | 0.84 | 0.82 | 0.66 | |
Average Payables |
0.86 | 0.87 | 1.11 | 1.07 | |
Average Inventory |
0.03 | 0.04 | 0.06 | 0.06 | |
Average Assets |
9.05 | 8.74 | 6.75 | 6.19 | |
Average Common Equity |
6.01 | 4.94 | 2.55 | 0.82 |
Columns are period end dates · fundamentals updated 26 Oct 2026